Strata Oncology Raises $12M in Series A Financing, Taps Thermo Fisher for Sequencing Tech | GenomeWeb

NEW YORK (GenomeWeb) – Strata Oncology said today that it has raised $12 million in a Series A financing to fuel its tumor sequencing operations.

The financing was co-led by Arboretum Ventures and Baird Capital, and included existing investor Michigan eLab. Ann Arbor, Michigan-based Strata said it will use the funds to implement the Strata Trial, a nationwide effort to increase the number of enrollments in precision medicine clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

Sponsored by
New England BioLabs

This webinar will provide an update on Phase 2 of the ongoing ABRF Next Generation Sequencing Study, an effort to evaluate the performance of NGS platforms and to identify optimal methods and best practices. Phase 1 of the study focused on RNA sequencing, while Phase 2 is focusing on genomic DNA samples.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.